Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Pain. 2016 Nov;157(11):2536–2543. doi: 10.1097/j.pain.0000000000000674

Fig. 3.

Fig. 3

Time-dependent changes in histamine in imiquimod-treated mice. A–E) Typical examples of histamine (green) and DAPI (blue) expression in the skin treated with imiquimod on day 0 (A), day 2 (B), and day 7 (C), and vehicle on day 2 (D), and day 7 (E). Scale bar indicates 500 μm. F) Triple fluorescence immunohistochemistry for expressions of histamine (green), Avidin (red), and DAPI (blue). Scale bar indicates 250 μm. G) Immunofluorescence intensity of histamine in the epidermis was measured using ImageJ in imiquimod-treated mice. Error bars are SEM (n = 4). *p< 0.05, significant difference from day 0, one-way ANOVA followed by Tukey test. H) Levels of histidine decarboxylase mRNA in the skin were measured using RT-qPCR. Error bars are SEM (n = 6). *p< 0.05, significant difference from day0, one-way ANOVA followed by Tukey test.

HHS Vulnerability Disclosure